ENTERA BIO LTD ENTX
SHS · Common Stock · CUSIP M40527109
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $1.75.
Trends to Q2 2020
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2019 | 4 |
| Q1 2020 | 4 |
| Q2 2020 | 6 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2020 | 1 | 1 |
| Q2 2020 | 2 | 2 |
Biggest buyers
| WEDBUSH SECURITIES INC | New | +30.0k |
| UBS Group AG | New | +10.4k |
Biggest sellers
| Wildcat Capital Management, LLC | Reduced | -48.6k |
| Phoenix Financial Ltd. | Reduced | -32.0k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
BIOTECHNOLOGY VALUE FUND L P
13D · may seek influence
new · filed 2026-08-04
Stated purposeThe Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. April Securities Purchase Agreement and Registration Rights Agreement On April 1, 2026, … Full filing |
10.0% |
| OPKO HEALTH, INC. 13G · passive investor new · filed 2025-04-02 | 8.1% |
| TCG Crossover GP III, LLC 13G · passive investor new · filed 2026-08-04 | 7.1% |
| Vivo Opportunity Fund Holdings, L.P. 13G · passive investor new · filed 2026-08-04 | 6.9% |
Fell to 5% or below in the last year: Longitude Capital Partners V, LLC (4.6%, 2026-08-04), Seven Fleet Capital Management LP (4.1%, 2026-08-04)
Insider purchases and sales in Q2 2020
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2020.
Holders, Q2 2020
| Manager | Shares | Change |
|---|---|---|
| Knoll Capital Management, LLC 1.74% of their portfolio | 1.7m $3.0m | Unchanged |
| Wildcat Capital Management, LLC 0.10% of their portfolio | 130.9k $269.0k | Reduced -48.6k |
| Phoenix Financial Ltd. 0.00% of their portfolio | 37.4k $66.0k | Reduced -32.0k |
| WEDBUSH SECURITIES INC 0.01% of their portfolio | 30.0k $55.0k | New |
| UBS Group AG 0.00% of their portfolio | 10.4k $19.0k | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |